Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94: 153–6.
   PubMed Web of Science ®Google Scholar
• Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 2003;17:357–64.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, . American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;7:6251–66.
   Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, , Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, , Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–103.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237–46.
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D Jr, Belani CP, . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149–58.
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, Pawel J von, . Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–37.
   PubMed Web of Science ®Google Scholar
• Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401–9.
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, . Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809–18.
   PubMed Web of Science ®Google Scholar
• Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, . Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26:4244–52.
   PubMed Web of Science ®Google Scholar
• Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, . Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307–14.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghanet DJ, . Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1–12.
   PubMedGoogle Scholar
• Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Egger M, Smith GR, Altman DG, Systematic reviews in health care: Meta-analysis in context. 2nd London, UK: BMJ Books; 2001 285–312.
   Google Scholar
• Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervaiset R, . Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744–52.
   PubMed Web of Science ®Google Scholar
• Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, . Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: Results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 2009;20:1483–8.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088–101.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629–34.
   PubMed Web of Science ®Google Scholar
• Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, . Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 2009;4:994–1001.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Douillard J, Fukuoka M, Saijo N, Kim S, Cufer T, . Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. J Clin Oncol 2009;27:15s (Suppl; abstr 8011).
   Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, . Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034–42.
   PubMed Web of Science ®Google Scholar